Banking
After Disappointing Phase 2 Data, Merck Drops Eye Disease Related Pact With NGM Biopharm
[ad_1]
<img class="img-responsive" src="https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2022/12/21/ngm_logo_light__58a0e6464f7ef4d049702f4c4705e5b5.png"><ul>
<li>Merck Co Inc (NYSE:<a class="ticker" href="https://markets.businessinsider.com/stocks/mrk-stock">MRK</a>) has notified NGM Biopharmaceuticals…
[ad_2]
<li>Merck Co Inc (NYSE:<a class="ticker" href="https://markets.businessinsider.com/stocks/mrk-stock">MRK</a>) has notified NGM Biopharmaceuticals…
[ad_2]
Share this news on your Fb,Twitter and Whatsapp
Times News Network:Latest News Headlines
Times News Network||Health||